Cancer
Sort
Members of ISB’s Heath Lab and their collaborators have developed a way to sensitively detect and analyze neoantigen-specific T-cell populations from tumors and blood. This promising development may have implications for creating targeted, individual-specific cancer vaccines.
By using single-cell analysis to measure metabolic activities in rare disseminated tumor cells taken from non-small cell lung cancer (NSCLC) patients, ISB researchers and their collaborators can accurately predict how patients will respond to various cancer therapies, and how treatments will impact a patient’s physiological performance and survival.
ISB’s Dr. Sui Huang uses the theory of complex systems and applies it to cancer research. In this video Q&A, he discusses the cancer paradox and highlights the importance of understanding the mechanism of why cancer treatments can backfire in order to open a new avenue for therapy and treatments.
ISB’s computational and bioinformatics teams played a central role in the completion of the PanCancer Atlas Initiative, the final phase of TCGA. The culmination of this work is being published in 27 papers this week across the Cell Press research journals, including “The Immune Landscape of Cancer” in Immunity.
Three organizations on the forefront of cancer immunotherapy, systems biology and bioinformatics announced the release of the Cancer Research Institute iAtlas, a comprehensive web-based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment.
Dead cells, or cell debris, generated by treatments intended to eradicate tumor cells actually act as strong stimulators of tumor progression. The findings of ISB cancer biologist Sui Huang, his former mentee and longtime collaborator Dipak Panigrahy at Beth Isreal Deaconess Medical Center in Boston, and colleagues at Harvard Medical School were published in The Journal of Experimental Medicine.